Measuring sustainable employability: psychometric properties of the capability set for work questionnaire

Autor: Sait Gürbüz, Margot C. W. Joosen, Dorien T. A. M. Kooij, Arnold B. Bakker, Jac J. L. van der Klink, Evelien P. M. Brouwers

Publikováno v: BMC Public Health, Vol 22, Iss 1, Pp 1-10 (2022)

Abstract Background The capability set for work questionnaire (CSWQ) is being used to measure the new model of sustainable employability building on the capability approach. However, previous studies on the psychometric properties of the instrument a

Externí odkaz: https://doaj.org/article/5f217f9068a642f39028e9b7fe6c6a8f

Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma

Autor: Marion de Jong, P. P. M. Kooij, Wouter W. de Herder, Theodosia Maina, Aad van der Lugt, Eric P. Krenning, Wout A.P. Breeman, Jack L. Erion, Marion Verdijsseldonck, Berthold A. Nock, Alida Froberg

Publikováno v: European Journal of Nuclear Medicine and Molecular Imaging, 36(8), 1265-1272. Springer-Verlag
European Journal of Nuclear Medicine and Molecular Imaging

Cholecystokinin 2 (CCK-2) receptor overexpression has been demonstrated in a high percentage of medullary thyroid carcinomas (MTC). Analogous to somatostatin receptors, CCK-2 receptors might be viable targets for radionuclide scintigraphy and/or radi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::055d4bf4d336deb04699b1fbc8b0acf5
https://doi.org/10.1007/s00259-009-1098-9

Treatment with the radiolabeled somatostatin analog [Lu-177-DOTA(0), Tyr(3)] octreotate: Toxicity, efficacy, and survival

Autor: Eric P. Krenning, Martijn van Essen, P. P. M. Kooij, Dik J. Kwekkeboom, Wouter W. de Herder, Casper H.J. van Eijck, Richard A Feelders, Maarten O. van Aken, Boen L. Kam

Publikováno v: Journal of Clinical Oncology, 26(13), 2124-2130. American Society of Clinical Oncology

Purpose Despite the fact that most gastroenteropancreatic neuroendocrine tumors (GEPNETs) are slow-growing, median overall survival (OS) in patients with liver metastases is 2 to 4 years. In metastatic disease, cytoreductive therapeutic options are l

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f339947c60ce4a98cebc081991ea86f
https://doi.org/10.1200/JCO.2007.15.2553

Comparison of [177Lu-DOTA0,Tyr3]octreotate and [177Lu-DOTA0,Tyr3]octreotide: which peptide is preferable for PRRT?

Autor: P. P. M. Kooij, Jaap J.M. Teunissen, A. van Gameren, Willem H. Bakker, Dirk Jan Kwekkeboom, Eric P. Krenning, Jan-Paul Esser

Publikováno v: European Journal of Nuclear Medicine and Molecular Imaging. 33:1346-1351

Patients with somatostatin receptor subtype 2-positive metastasised neuroendocrine tumours can be treated with [(177)Lu-DOTA(0),Tyr(3)]octreotate. Some use octreotide as the peptide for peptide receptor radionuclide therapy (PRRT). We compared in sev

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4188899295935eb0e90b3e6132d1896
https://doi.org/10.1007/s00259-006-0172-9

Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspective

Autor: Roelf Valkema, Willem H. Bakker, P. P. M. Kooij, Theo J. Visser, Marion de Jong, Eric P. Krenning, Dik J. Kwekkeboom, Wout A.P. Breeman

Publikováno v: European Journal of Nuclear Medicine, 28(9), 1421-1429. Springer-Verlag

In vivo somatostatin receptor-mediated scintigraphy has proven to be a valuable method for the visualisation of neuroendocrine tumours and their metastases. A new application is the use of radiolabelled analogues for somatostatin receptor-mediated th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d21b1fdd15b72cfc17b5c5a2029ef0ed
https://doi.org/10.1007/s002590100502